Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Oregon: - Oregon Health and Science University — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Oregon: - Investigative Site US042 — Portland, Oregon
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to assess the safety and efficacy of BMS-986504, a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination with nab-p/gem, in partici…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07076121
Sites in Oregon: - Kaiser Permanente Center for Health Research — Portland, Oregon
- Local Institution - 0162 — Portland, Oregon
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Oregon: - Oregon Health and Science University Physicians Pavilion (Adults and Pediatrics) — Portland, Oregon
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Oregon: - Exelixis Clinical Site #27 — Portland, Oregon
Phase 2, Phase 3 Recruiting Industry
Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ducta…
Sponsor: Pfizer
NCT ID: NCT06989437
Sites in Oregon: - OHSU Center for Health & Healing 1 — Portland, Oregon
- Oregon Health and Science University — Portland, Oregon
- OSHU Center for Health and Healing 2 — Portland, Oregon
Phase 3 Recruiting Academic/Other
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Sponsor: Rezolute
NCT ID: NCT06881992
Sites in Oregon: - Investigative Site — Portland, Oregon
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Oregon: - Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
- Providence Newberg Medical Center — Newberg, Oregon
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab or docetaxel in participants with advanced solid tumors. This study is a first-in-human…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in Oregon: - Providence Cancer Center Oncology and Hematology Care- Eastside — Portland, Oregon
Phase 1, Phase 2 Recruiting Industry
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
Sponsor: Cantex Pharmaceuticals
NCT ID: NCT05766748
Sites in Oregon: - Williamette Valley Cancer Institute and Research Center — Eugene, Oregon
Phase 1 Recruiting Industry
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will study sigvotatug vedotin to find out wh…
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
NCT ID: NCT04389632
Sites in Oregon: - Providence Cancer Institute Franz Clinic — Portland, Oregon
- Providence Oncology and Hematology Care Clinic - Westside — Portland, Oregon
- Providence St. Vincent Medical Center- Investigational Drug Services — Portland, Oregon
- Providence St. Vincent Medical Center — Portland, Oregon
Phase 1 Recruiting Industry
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.
Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in Oregon: - Research Site — Portland, Oregon
EARLY Phase 1 Recruiting Academic/Other
This early phase I trial studies the biological activity of OMO-103 in patients with pancreatic ductal adenocarcinoma that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primar…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT07089940
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
EARLY Phase 1 Recruiting Academic/Other
This early phase I trial aims to determine how cobimetinib, olaparib, onvansertib, azenosertib, AZD5305 or tremelimumab works in patients with pancreatic cancer. Validation of cobimetinib, olaparib, onvansertib azenosertib, AZD5305 and tre…
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT04005690
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oregon: - Saint Alphonsus Cancer Care Center-Baker City — Baker City, Oregon
- Saint Charles Health System — Bend, Oregon
- Clackamas Radiation Oncology Center — Clackamas, Oregon
- Providence Cancer Institute Clackamas Clinic — Clackamas, Oregon
- Bay Area Hospital — Coos Bay, Oregon
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oregon: - Massive Bio SYNERGY-AI site — Portland, Oregon
Recruiting Academic/Other
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individ…
Sponsor: Arbor Research Collaborative for Health
NCT ID: NCT04970056
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Recruiting Academic/Other
This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when t…
Sponsor: Mayo Clinic
NCT ID: NCT06271291
Sites in Oregon: - Oregon Health & Science University — Portland, Oregon
Recruiting Academic/Other
This study evaluates the use of indocyanine green to predict postoperative pancreatic leaks in patients undergoing transection of the pancreas.
Sponsor: OHSU Knight Cancer Institute
NCT ID: NCT06084013
Sites in Oregon: - OHSU Knight Cancer Institute — Portland, Oregon